Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular mechanisms and drug targets without original human data or systematic methodology.
PubMed 26136385 · doi:10.1002/cmdc.201500188
What was done
This narrative review summarizes molecular mechanisms of Toll-like receptor 4 (TLR4) activation involving accessory proteins like MD2, LBP, and CD14. It reviews how TLR4 activation triggers nervous system signaling pathways related to chronic pain and opioid tolerance/dependence, and discusses small-molecule versus peptide-based TLR4 agonists and antagonists (such as eritoran, MD2-I, and tricyclic antidepressants).
What was found
The abstract reports qualitative mechanistic descriptions of the TLR4-MD2-LPS complex and signaling pathways. Small-molecule modulators are highlighted as advantageous over peptides due to oral administration and lower cost. No specific quantitative numbers, effect sizes, or trial statistics are reported in the abstract.
Why it matters
Targeting TLR4 signaling pathways offers a mechanistic approach to developing treatments for neuroinflammation, chronic pain, and opioid dependence.
Limits
As a narrative review, no original clinical or experimental data are presented in the abstract. No quantitative results, sample sizes, or systematic review search criteria are provided.
Cited by
- supports Lipopolysaccharides (LPS) drive pain through interactions with the central nervous system.